Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 76.52% is in line with its 5-year average of 81.39%, near the low end of its 5-year range (74.82%–85.43%).
0.81% below its 12-month average of 77.15%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 74.82%.
GROSS MARGIN
76.52%
GROSS MARGIN AVG TTM
77.15%
GROSS MARGIN AVG 3Y
79.70%
GROSS MARGIN AVG 5Y
81.39%
GROSS MARGIN AVG 10Y
83.44%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.81%
CURRENT VS 3Y AVG
-3.99%
CURRENT VS 5Y AVG
-5.98%
CURRENT VS 10Y AVG
-8.30%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 724 covered companies
CURRENT VS SECTOR MEDIAN
+89.50%
vs the sector median at left
Market Cap
$802.16M
Gross Margin
94.30%
TTM Avg
95.84%
3Y Avg
95.72%
5Y Avg
72.44%
Market Cap
$795.90M
Gross Margin
10.37%
TTM Avg
19.20%
3Y Avg
18.44%
5Y Avg
17.81%
Market Cap
$789.58M
Gross Margin
97.42%
TTM Avg
97.90%
3Y Avg
98.95%
5Y Avg
-3197.94%
Market Cap
$788.34M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$825.69M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$819.99M
Gross Margin
35.97%
TTM Avg
27.94%
3Y Avg
30.11%
5Y Avg
34.47%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMode Ltd. (INMD) | $805.36M | 76.52% | 77.15% | 79.70% | 81.39% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $802.16M | 94.30% | 95.84% | 95.72% | 72.44% |
| Ardelyx, Inc. (ARDX)vs › | $812.21M | 93.96% | 87.19% | 88.05% | 90.06% |
| AdaptHealth Corp. (AHCO)vs › | $795.90M | 10.37% | 19.20% | 18.44% | 17.81% |
| Geron Corporation (GERN)vs › | $789.58M | 97.42% | 97.90% | 98.95% | -3197.94% |
| Apnimed, Inc. (APMD)vs › | $792.48M | N/A | N/A | N/A | N/A |
| Sana Biotechnology, Inc. (SANA)vs › | $788.34M | 0.00% | 0.00% | 0.00% | 0.00% |
| Jade Biosciences, Inc. (JBIO)vs › | $825.69M | 0.00% | 0.00% | 0.00% | 0.00% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $819.99M | 35.97% | 27.94% | 30.11% | 34.47% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $781.61M | 40.44% | 20.22% | 20.22% | 20.22% |
Gross Margin
76.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 74.82% |
| 2026-03-31 | 75.05% |
| 2025-12-31 | 78.28% |
| 2025-09-30 | 77.61% |
| 2025-06-30 | 79.97% |
| 2025-03-31 | 78.22% |
| 2024-12-31 | 79.34% |
| 2024-10-31 | 81.53% |
| 2024-06-30 | 80.20% |
| 2024-03-31 | 79.62% |
| 2023-12-31 | 84.02% |
| 2023-09-30 | 83.64% |
| 2023-06-30 | 83.79% |
| 2023-03-31 | 82.79% |
| 2022-12-31 | 84.28% |
| 2022-09-30 | 84.52% |
| 2022-06-30 | 83.31% |
| 2022-03-31 | 82.81% |
| 2021-12-31 | 84.76% |
| 2021-09-30 | 85.19% |
| 2021-06-30 | 85.43% |
| 2021-03-31 | 84.62% |
| 2020-12-31 | 85.94% |
| 2020-09-30 | 84.27% |
| 2020-06-30 | 84.74% |
| 2020-03-31 | 84.71% |
| 2019-12-31 | 87.14% |
| 2019-09-30 | 87.39% |
| 2019-06-30 | 87.43% |
| 2019-03-31 | 86.02% |
| 2018-12-31 | 86.31% |
| 2018-09-30 | 85.57% |
| 2018-06-30 | 84.36% |
| 2018-03-31 | 83.11% |
| 2017-12-31 | 82.05% |
| 2017-09-30 | 85.48% |
| 2017-06-30 | 83.23% |
| 2017-03-31 | 82.32% |
